Low- or no-opioid pain control is possible with EXPAREL

EXPAREL® (bupivacaine liposome injectable suspension), is a local analgesic administered at the time of surgery to control pain and reduce or eliminate the use of opioids for acute postsurgical pain. When injected into the surgical site, EXPAREL turns off the body’s pain signals, numbing the area where surgery has occurred for several days following the procedure. To date, EXPAREL has been used in over 4.5 million patients.1

EXPAREL infiltration provides significant long-lasting pain control while reducing opioid use

EXPAREL vs bupivacaine HCI in total knee arthoplasty (TKA)2

Results from an EXPAREL Phase 4, double-blind, randomized controlled trial that compared the efficacy and safety of EXPAREL 266 mg (20 mL) (n=70) and bupivacaine HCl (n=69) in TKA. Primary endpoints: area under the curve of visual analog scale pain intensity scores 12–48 hours postsurgery; total opioid consumption 0–48 hours postsurgery. Rescue opioids for pain were available upon patient request. Rates and types of adverse events were similar between treatment groups. The most common adverse events were nausea, dizziness and muscle spasms.

Data from patients undergoing a soft-tissue surgery3,4

Results from a Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group clinical trial that evaluated the safety and efficacy of 266mg (20ml) EXPAREL in 186 patients undergoing 2- or 3-column excisional hemorrhoidectomy. Primary endpoint: cumulative pain score reflected in area under the curve of numeric rating scale through 72 hours. Placebo was preservative-free saline for injection. Opioid rescue medication (up to 10 mg IM morphine ) was available to all patients.

*Results vs placebo through 72 hours. Opioid reduction calculated based on geometric mean ratio.

Excellent results with EXPAREL in a single shot in interscalene brachial plexus nerve block

Significant postsurgical pain relief that lasts 48 hours with EXPAREL

VAS pain intensity scores with interscalene brachial plexus nerve block5

Primary endpoint was area under the curve (AUC) of the visual analog scale (VAS) pain intensity scores; 136 vs 254 (LSMD -118) for EXPAREL and placebo, respectively2,5

PACU=postanesthesia care unit. LSMD=least squares mean difference. Results from a phase 3 double-blind, randomized, controlled trial that compared the postsurgical analgesia efficacy, safety, and pharmacokinetics of EXPAREL 133 mg (10 mL) and placebo in patients undergoing total shoulder arthroplasty or rotator cuff repair. Primary and secondary endpoints: pain intensity through 48 hours postsurgery, as measured by area under the curve (AUC) of visual analog scale (VAS) pain intensity scores and total postsurgical opioid consumption. Rescue opioids for pain were available upon patient request.

78% reduction in opioids through 48 hours

Postsurgical opioid consumption6

The clinical benefit of the decrease in opioid consumption was not demonstrated in the clinical trials